Malwine J. Barz

Schleswig, SH, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

Journal: HemaSphere
Published: September 30, 2025

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Journal: HemaSphere
Published: September 09, 2025

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Journal: HemaSphere
Published: August 14, 2025

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

Journal: Blood
Published: August 04, 2025

IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

Journal: Blood
Published: August 04, 2025

RoCK and ROI: single-cell transcriptomics with multiplexed enrichment of selected transcripts and region-specific sequencing.

RoCK and ROI: single-cell transcriptomics with multiplexed enrichment of selected transcripts and region-specific sequencing.

Journal: Nature communications
Published: June 18, 2024

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.

Journal: Blood
Published: July 05, 2023

The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age.

The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age.

Journal: HemaSphere
Published: April 19, 2023

B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow.

B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow.

Journal: Haematologica
Published: December 02, 2021

X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.

X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.

Journal: EMBO molecular medicine
Published: May 14, 2021

Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse.

Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse.

Journal: Nature cancer
Published: November 12, 2020

The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.

The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.

Journal: Blood advances
Published: September 06, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026